MedTrace Logo

Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)

NCT00857012 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2313

Last updated 2012-11-12

No results posted yet for this study

Summary

Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment ("switch") for at least three and not more than six months prior to offering an individual participation in this program. Treatment should follow local therapy guidelines and standard practice. Treatment decisions for patients participating in this study including assessments or supportive therapy during follow-up visits will also follow guidelines and remain independent of the program.

Conditions

Sponsors & Collaborators

Principal Investigators

  • H Brasch · AstraZeneca, Germany

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Completion
2012-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857012 on ClinicalTrials.gov